Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Oncology
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Drug Development
Small Molecule Research & Development
Oncology
Fierce 50
Special Report
Awards Gala
Awards
Outsourcing Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Subscribe
Biotech
Cell & Gene Therapy
Clinical Data
Oncology
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Drug Development
Small Molecule Research & Development
Oncology
Fierce 50
Special Report
Awards Gala
Awards
Outsourcing Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
TScan Therapeutics
Biotech
TScan’s strategy unaffected by Amgen scrapping $500M+ collab
“There are no planned changes to our wholly owned programs as a result of the Amgen collaboration being terminated,” TScan told Fierce.
Darren Incorvaia
Aug 19, 2026 5:31pm
TScan lays off 30% of workforce, halts solid tumor TCR trial
Nov 3, 2025 8:25am
BIO, Seaport, Orna and more—Chutes & Ladders
Apr 12, 2024 8:30am
Takeda welcomes new oncology chief from CRISPR—Chutes & Ladders
Feb 9, 2024 9:30am
Former Arena CEO takes over new RNA biotech—Chutes & Ladders
May 26, 2023 9:30am
TScan adds another $100M to the pot for TCR therapies
Jan 25, 2021 8:20am
